ASCO lifts embargo early on study of breast cancer drug T-DM1 after break
In what has become an annual ritual, the American Society of Clinical Oncology (ASCO) meeting now underway in Chicago has been the subject of an embargo break. From a message sent by ASCO last night to reporters:
Due to an embargo break, the embargo is now lifted on abstract #LBA1 “Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer” being presented at the ASCO Annual Meeting in Chicago. (The embargo was originally scheduled to lift at 12:01am EDT Sunday, June 3.)
The earliest story in my Google News timeline is this one from the Daily Mail, which posted at 5:21 p.m. Eastern yesterday, nearly seven hours before the scheduled embargo, but that doesn’t mean it’s them who broke the embargo, since not everything shows up there.
An ASCO spokesperson would not name the breaker, telling Embargo Watch that they are dealing with the break internally and did not have further comment.
Hat tip: Serena Stockwell
